Medpace Holdings, Inc. (MEDP) Stock: Price, Forecast & Analyst Target
Medpace Holdings, Inc. (MEDP) — MoonshotScore 92/100 (Exceptional band), calculated Nov 18, 2026. Price $633.98 (-1.99%), as of the Nov 19, 2026 trading session; market cap $17.7B.
Educational signal · not a buy or sell recommendation · How to read this
Medpace Holdings, Inc. · MEDP · NASDAQ · Healthcare · Medical - Diagnostics & Research
Research dated 2026-09-12: Medpace is an outsourced clinical-development operator serving pharmaceutical, biotechnology and medical-device sponsors, not a diagnostics manufacturer selling tests or instruments. Its appeal rests on whether broad trial execution can resume meaningful growth after revenue recently flattened while preserving strong operating profitability and cash generation.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Medpace Holdings (MEDP)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a strong balance sheet and elite growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- Altman Z 8.09 · Piotroski F 8
- ROE 117.9% · ROA 18.7% · current ratio 0.83
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 93 | Exceptional | |
| 93 | Exceptional | |
| 93 | Exceptional | |
| 93 | Exceptional | |
| 92 | Exceptional | |
| 92 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $633.98 | |
| Change on the day | -1.99% | |
| 52-week range | $373.00–$693.97 | |
| Market capitalisation | $17.7B | — |
| Price / earnings (trailing) | 35.57 | |
| Shares traded on the day | 167.8K | |
| Beta (volatility vs the S&P 500) | 1.12 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Medpace Holdings (MEDP): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company less favourably than the MoonshotScore does: Englander-style lens and Munger lens (margin of safety). Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Medpace Holdings (MEDP), and what does it report?
Short answer · as of
Sponsors hire Medpace to design and manage clinical programs, coordinate laboratories and imaging, handle data and regulatory work, monitor safety, and support submissions and post-marketing studies.
Research dated 2026-09-12.
Demand therefore follows the volume and scope of client development programs rather than sales of Medpace-owned therapies.
Reported revenue aggregates that service activity across therapeutic areas. Oncology and metabolic programs are the largest disclosed revenue pools, with cardiology, central nervous system work and other programs adding diversification.
What do the latest results show for Medpace Holdings (MEDP)?
Research dated 2026-09-12.
Annual revenue and net income rose throughout the period shown, and quarterly revenue advanced sharply before settling into a narrow range recently. In the latest period, gross profit and operating profit improved despite nearly unchanged revenue, while net income and diluted earnings softened modestly.
Reported earnings and revenue have repeatedly exceeded prevailing estimates across recent releases. Management subsequently updated its net-income outlook, incorporating tax, interest-income and repurchase assumptions rather than attributing the latest result to a new operating mechanism.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $660M | $111M | $3.86 (diluted) |
| Q4 FY2025 | $708M | $135M | $4.67 (diluted) |
| Q1 FY2026 | $707M | $124M | $4.28 (diluted) |
| Q2 FY2026 | $707M | $121M | $4.25 (diluted) |
What are the financial strengths and risks for Medpace Holdings (MEDP)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Operating cash flow remained positive throughout the quarterly series and generally exceeded capital spending by a wide margin. Cash and short-term investments exceed total debt, leaving Medpace with net cash and substantial internal funding capacity.
Liquidity still deserves scrutiny. Cash has moved sharply between periods and declined across the full reported window, while the current ratio remains below parity and total liabilities exceed the cash balance. The market value also dwarfs net cash, so the valuation depends far more on continued earnings execution than on balance-sheet assets.
A broad slowdown in client clinical-development activity would pressure service demand, with weakness in oncology or metabolic programs carrying particular weight. If revenue remains flat while operating costs rise, the recent benefit from operating leverage would reverse.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 35.57 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
What should you watch next at Medpace Holdings (MEDP)?
Short answer · as of
Current published price targets run low $515.00 · high $730.00 · consensus $649.27 · median $673.00 against a quoted price of $633.98 (as of Nov 19, 2026).
Research dated 2026-09-12.
Revenue progression is the immediate operating test: recent periods show a plateau after a strong advance. Watch whether gross profit and operating profit can keep improving without renewed top-line momentum, and whether operating cash flow continues to translate accounting earnings into cash.
The scheduled earnings release also provides a direct comparison with expectations for renewed revenue and earnings growth. Beyond that release, consensus estimates assume continued expansion, making any sustained divergence in revenue, margins or cash conversion especially informative.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Medpace Holdings compare with its peers?
Short answer
Medpace Holdings's score ranks 2nd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Medpace is better understood as an integrated clinical-development partner than as a conventional diagnostics company or a biotechnology developer. It earns service revenue by running client programs across the development lifecycle rather than relying on sales of an owned drug.
Its operating breadth combines trial management with central laboratory work, bio-analytical testing, imaging, electrocardiography, data services, safety monitoring and regulatory support. The therapeutic revenue mix is led by oncology and metabolic programs, so diversification comes from both service breadth and exposure to distinct areas of clinical research.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1705.66 Nov 19, 2026 | $33.9B | 93 5-pillar Nov 18, 2026 | |
| Medpace Holdings (MEDP) — this page | $633.98 | $17.7B | 92 |
| $65.62 Nov 19, 2026 | $32.5B | 91 5-pillar Nov 18, 2026 | |
| $210.01 Nov 18, 2026 | $31.8B | 84 5-pillar Nov 18, 2026 | |
| $29.83 Nov 19, 2026 | $12.5B | 84 5-pillar Nov 18, 2026 | |
| $49.63 Nov 19, 2026 | $10.3B | 83 5-pillar Nov 18, 2026 | |
| $258.99 Nov 19, 2026 | $28.5B | 74 5-pillar Nov 18, 2026 | |
| $190.36 Nov 19, 2026 | $14.3B | 73 5-pillar Nov 18, 2026 | |
| $151.59 Nov 19, 2026 | $16.9B | 71 5-pillar Nov 18, 2026 | |
| $370.78 Nov 18, 2026 | $30.1B | 71 5-pillar Nov 18, 2026 | |
| $257.84 Nov 18, 2026 | $42.5B | 71 5-pillar Nov 18, 2026 | |
| $327.93 Nov 19, 2026 | $15.7B | 70 5-pillar Nov 18, 2026 | |
| $289.50 Nov 18, 2026 | $42.0B | 36 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $515.00 – $730.00
- Consensus target
- $649.27
- Median target
- $673.00
Consensus record · Captured .
Measured against a quoted price of $633.98 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Oct 29, 2026
- Transactions
- 60
- Identified insiders
- 8
- Purchases
- 0
- Sales
- 32
- Other transactions
- 28
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held MEDP in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.16% | $35.89M | Added +268.5% shares |
| Fundsmith | Terry Smith | Q3 2026 | 0.13% | $16.19M | Trimmed −50.5% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Medpace Holdings (MEDP)?
MEDP Healthcare Stock FAQ
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Medpace actually sell to drug and device developers?
Medpace sells coordinated clinical-development services spanning program design, trial execution, laboratory and imaging support, data management, safety monitoring, regulatory work and post-marketing support. Revenue reflects work performed for sponsors, not commercial sales of Medpace-owned treatments.
Why are oncology and metabolic programs so important to Medpace?
Oncology and metabolic work form the largest disclosed therapeutic revenue pools. Changes in sponsor activity across those programs can therefore have an outsized effect on Medpace’s overall growth.
How capital intensive is Medpace’s clinical-development model?
Capital spending has generally remained modest beside operating cash flow, indicating that recent growth has not required comparable investment in physical assets. The latest rise in spending is worth tracking because persistence would change that cash-conversion profile.
What would break Medpace’s recent earnings pattern?
Sustained weakness in contracted clinical-development activity, especially across the largest therapeutic programs, would remove the revenue support behind operating leverage. Margin deterioration or weaker cash conversion during a revenue plateau would provide an early sign that the pattern has changed.
What is the MEDP stock price today?
The last price recorded for Medpace Holdings, Inc. (MEDP), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the MEDP price target?
The analyst consensus price target for Medpace Holdings, Inc. (MEDP), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 20 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold MEDP
Funds in our ETF coverage that list MEDP among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| ERShares Private-Public Crossover ETF (XOVR) | 3.17% | |
| Invesco S&P MidCap Quality ETF (XMHQ) | 2.71% |